TY - JOUR
T1 - Propranolol
T2 - What is BLOCKing its clinical investigation in breast cancer?
AU - Blaes, Anne H.
AU - Domingo-Musibay, Evidio
AU - Kalinsky, Kevin
N1 - Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/4/15
Y1 - 2020/4/15
N2 - Presurgical propranolol modulates biomarkers associated with breast cancer progression. β-adrenergic signaling promotes invasion, epithelial-to-mesenchymal transition phenotype, and immune cell infiltration into the tumor microenvironment. Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis.
AB - Presurgical propranolol modulates biomarkers associated with breast cancer progression. β-adrenergic signaling promotes invasion, epithelial-to-mesenchymal transition phenotype, and immune cell infiltration into the tumor microenvironment. Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis.
UR - http://www.scopus.com/inward/record.url?scp=85083487794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083487794&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-19-3818
DO - 10.1158/1078-0432.CCR-19-3818
M3 - Article
C2 - 32029438
AN - SCOPUS:85083487794
SN - 1078-0432
VL - 26
SP - 1781
EP - 1783
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 8
ER -